FICHIT

Je m'inscris

ACELRX

0/5 (0 note(s))
Note donnée : aucune
United States
130
Development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.
Zalviso™, our lead program, has completed Phase 3 development and an NDA has been submitted to the FDA seeking its approval. The product was developed to address some of the challenges associated with intravenous patient-controlled analgesia (IV PCA), which is the standard means of treating moderate-to-severe acute pain in the hospital setting.
ARX-02 is a potential new treatment option for patients who suffer from breakthrough pain (BTP) due to cancer that has completed Phase 2 development.
ARX-03 is a sublingual product candidate designed to provide non-invasive mild sedation, anxiety reduction and pain relief in patients prior to a painful procedure in a physician’s office. ARX-03 has completed Phase 2 development.
ARX-04 a sublingual sufentanil product candidate designed to provide a non-invasive, fast-onset treatment of patients with moderate-to-severe acute pain, both on the battlefield and in civilian settings of trauma or injury.
MORRIS Timothy
www.acelrx.com
ACRX:US

Fiche créée le 10/04/2016 par Guillaume   vue 35 fois.